SCHEDULE: C/M Capital Reports 0% Stake in Salarius Pharma
Beneficial Ownership Report
C/M Capital Master Fund and related entities filed a Schedule 13G, reporting zero beneficial ownership in Salarius Pharmaceuticals, Inc. as of October 7, 2025.
Summary
- C/M Capital Master Fund, LP, C/M Capital Partners, LP, Thomas Walsh, and Jonathan Juchno are the reporting persons for this Schedule 13G filing.
- As of October 7, 2025, the reporting persons beneficially owned 0.00 shares of Salarius Pharmaceuticals, Inc. Common Stock.
- This represents 0% of the outstanding Common Stock of Salarius Pharmaceuticals, Inc.
- The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.
- C/M Capital Partners, LP serves as the investment manager to C/M Capital Master Fund, LP.
- Thomas Walsh and Jonathan Juchno are the managing members of the general partner of C/M Capital Partners, LP.
Sentiment
Score: 5
Explanation: The filing is a routine Schedule 13G reporting zero beneficial ownership, providing no positive or negative financial or operational information about the issuer.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Salarius Pharmaceuticals, Inc.'s future performance or operations.
Management Comments
- Messrs. Walsh and Juchno disclaim beneficial ownership of any shares of Common Stock that were held by C/M Master Fund.
Industry Context
This filing is a routine disclosure of beneficial ownership, indicating that the reporting entities do not hold a significant stake in Salarius Pharmaceuticals, Inc. It does not provide specific insights into broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Minimal impact, as the filing indicates no significant ownership by the reporting entities, suggesting no immediate change in control or influence.
Key Dates
| Date | Description |
|---|---|
| 10/07/2025 | Date of event which requires the filing of this statement, indicating zero beneficial ownership. |
| 10/14/2025 | Date the Schedule 13G statement was signed and filed by the reporting persons. |
Keywords
Salarius Pharmaceuticals, C/M Capital Master Fund, C/M Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.